Sign in
Active, not recruitingPhase 2

Conditioning SCID Infants Diagnosed Early

Key facts

Who runs it
Center for International Blood and Marrow Transplant Research
Where
Ann Arbor, Atlanta, Aurora, Birmingham, Boston, Charlotte, Chicago, Cincinnati, Dallas, Durham, Gainesville, Grand Rapids, Hackensack, Kansas City, Los Angeles, Madison, Miami, Milwaukee, Minneapolis, Nashville, New Orleans, New York, Omaha, Philadelphia, Phoenix, Pittsburgh, Portland, Queens, Salt Lake City, San Diego, San Francisco, Seattle, St. Petersburg, and Washington D.C., United StatesSee the 35 sitesAlso in 1 other country, 3 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
56 people, planned
Started
22 Oct 2018
Expected to end
1 Dec 2028
Type of study
Interventional, 2 groups
Treatments tested
  • Busulfan
  • Cell processing for TCRαβ+/CD19+ depletion
Record updated
16 November 2026

Who can take part

Age
0 years to 2 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Infants with SCID, either typical or leaky or Omenn syndrome
  • Typical SCID is defined as either of the following; Absence or very low number of T cells (CD3+ T cells <300/microliter AND no or very low T cell function (<10% of lower limit of normal) as measured by response to phytohemagglutinin OR; Presence of maternally derived T cells
  • Leaky SCID is defined as the following; Absence of maternally derived T cells; AND either one or both of the following (i, ii): i) <50% of lower limit of normal T cell function as measured by response to PHA OR <30% of lower limit of normal T cell function as measured by response to CD3 ii) Absent or <10% of lower limit of normal proliferative responses to candida and tetanus toxoid antigens (must document post vaccination or exposure for this criterion to apply); AND at least two of the following (i through iii): i) CD3 T cells < 1500/microliter ii) >80% of CD3+ or CD4+ T cells are CD45RO+ AND/OR >80% of CD3+ or CD4+ T cells are CD62L negative AND/OR >50% of CD3+ or CD4+ T cells express HLA-DR (at < 4 years of age) AND/OR are oligoclonal T iii) Low TRECs and/or the percentage of CD4+/45RA+/CD31+ or CD4+/45RA+/CD62L+ cells is below the lower level of normal
  • Omenn syndrome • Generalized skin rash; Maternal lymphocytes tested for and not detected; >80% of CD3+ or CD4+ T cells are CD45RO+ AND/OR >80% of CD3+ or CD4+ T cells are CD62L negative AND/OR >50% of CD3+ or CD4+ T cells express HLA-DR (<2 years of age); Absent or low (up to 30% lower limit of normal (LLN)) T cell proliferation to antigens (Candida, tetanus) to which the patient has been exposed IF: Proliferation to antigen was not performed, but at least 4 of the following 8 supportive criteria, at least one of which must be among those marked with an asterisk (*) below are present, the patient is eligible as Omenn Syndrome; Hepatomegaly; Splenomegaly; Lymphadenopathy; Elevated IgE; Elevated absolute eosinophil count; *Oligoclonal T cells measured by CDR3 length or flow cytometry (upload report); *Proliferation to PHA is reduced to < 50% of lower limit of normal (LLN) or SI < 30; *Low TRECs and/or percentage of CD4+/RA+ CD31+ or CD4+/RA+ CD62L+ cells below the lower level of normal; Documented mutation in one of the following SCID-related genes
  • Cytokine receptor defects (IL2RG, JAK3) b. T cell receptor rearrangement defects (RAG1, RAG2) 3. No available genotypically matched related donor (sibling) 4. Availability of a suitable donor and graft source
  • Haploidentical related mobilized peripheral blood cells
  • 9/10 or 10/10 allele matched (HLA-A, -B, -C, -DRB1, -DQB1) volunteer unrelated donor mobilized peripheral blood cells 5. Age 0 to 2 years at enrollment; Note: to ensure appropriate hepatic metabolism, age at time of busulfan start:; For IL2RG/JAK3: 8 weeks For RAG1/RAG2: 12 weeks
  • Adequate organ function defined as:
  • Cardiac:; Left ventricular ejection fraction (LVEF) at rest ≥ 40% or, shortening fraction (SF) ≥ 26% by echocardiogram
  • Hepatic:; Total bilirubin < 3.0 x the upper limit of normal (ULN) for age (patients who have been diagnosed with Gilbert's Disease are allowed to exceed this limit) and AST and ALT < 5.0 x ULN for age
  • Renal:; GFR estimated by the updated Schwartz formula ≥ 90 mL/min/1.73 m2. If the estimated GFR is < 90 mL/min/1.73 m2, then renal function must be measured by 24-hour creatinine clearance or nuclear GFR, and must be > 50 mL/min/1.73 m2
  • Pulmonary No need for supplemental oxygen and O2 saturation > 92% on room air at sea level (with lower levels allowed at higher elevations per established center standard of care)

Who cannot take part

  • Presence of any serious life-threatening or opportunistic infection at time of enrollment and prior to the initiation of the preparative regimen. Serious infections as defined below that occur after enrollment must be reported immediately to the Study Coordinating Center, and enrollment will be put on hold until the infection resolves. Ideally enrolled subjects will not have had any infection. If patients have experienced infections, these must have resolved by the following definitions:; Bacterial i. Positive culture from a sterile site (e.g. blood, CSF, etc.): Repeat culture(s) from same site must be negative and patient has completed appropriate course of antibacterial therapy (typically at least 10 days); Tissue-based clinical infection (e.g. cellulitis): Complete resolution of clinical signs (e.g. erythema, tenderness, etc.) and patient has completed appropriate course of antibacterial therapy (typically at least 10 days); Pneumonia, organism not identified by bronchoalveolar lavage: Complete resolution of clinical signs (e.g. tachypnea, oxygen requirement, etc.) and patient has completed appropriate course of antibacterial therapy (typically at least 10 days). If possible, radiographic resolution should also be demonstrated; Fungal i. Positive culture from a sterile site (e.g. blood, CSF, etc.): Repeat culture(s) from same site is negative and patient has completed appropriate course of antifungal therapy (typically at least 14 days). The patient may be continued on antifungal prophylaxis following completion of the treatment course; Pneumocystis i. Complete resolution of clinical signs (e.g. tachypnea, oxygen requirement, etc.) and patient has completed appropriate course of therapy (typically at least 21 days). If possible, radiographic resolution should also be demonstrated. The patient may be continued on prophylaxis following completion of the treatment course; Viral i. Viral PCRs from previously documented sites (blood, nasopharynx, CSF) must be re-tested and are negative; If re-sampling a site is not clinically feasible (i.e. BAL fluid): Complete resolution of clinical signs (e.g. tachypnea, oxygen requirement, etc.). If possible, radiographic resolution should also be demonstrated
  • Patients with HIV or HTLV I/II infection will be excluded

Where in United States

Also in 1 other country, 3 sites

  • The University of MichiganAnn Arbor, United States
  • Children's Healthcare of Atlanta at EglestonAtlanta, United States
  • University of Colorado - Children's HospitalAurora, United States
  • Univeristy of Alabama at BirminghamBirmingham, United States
  • Dana Farber Cancer Institute - PedsBoston, United States
  • Levine Children's HospitalCharlotte, United States
  • Comer Children's Hospital/University of Chicago MedicineChicago, United States
  • Cincinnati Children's Hospital Medical CenterCincinnati, United States
  • Children's Medical Center DallasDallas, United States
  • Duke University Medical Center; Pediatric Blood and Marrow TransplantDurham, United States
  • Shands HealthCare & University of FloridaGainesville, United States
  • Helen DeVos Children'sGrand Rapids, United States
  • Hackensack University Medical CenterHackensack, United States
  • The Children's Mercy Hospitals and ClinicsKansas City, United States
  • Children's Hospital Los AngelesLos Angeles, United States
  • UCLA Center for Health SciencesLos Angeles, United States
  • University of Wisconsin Hospital and ClinicsMadison, United States
  • University of Miami/ Jackson Memorial HospitalMiami, United States
  • Children's Hospital of WisconsinMilwaukee, United States
  • University of Minnesota Blood and Marrow Transplant Program - PediatricsMinneapolis, United States
  • Vanderbilt University Medical CenterNashville, United States
  • Children's Hospital / LSUHSCNew Orleans, United States
  • Morgan Stanley Children's Hospital of New York-Presbyterian - Columbia University Medical CenterNew York, United States
  • Nebraska MedicineOmaha, United States
  • Children's Hospital of PhiladelphiaPhiladelphia, United States
  • Mayo Clinic Arizona and Phoenix Children's HospitalPhoenix, United States
  • Children's Hospital of Pittsburgh of UPMCPittsburgh, United States
  • Oregon Health and Science UniversityPortland, United States
  • Cohen Children's Medical CenterQueens, United States
  • Utah Blood and Marrow Transplant Program-PedsSalt Lake City, United States
  • Rady Children's Hospital - San DiegoSan Diego, United States
  • University of California San Francisco Medical Center - PedsSan Francisco, United States
  • Fred Hutchinson Cancer Center / Seattle Children'sSeattle, United States
  • All Children's HospitalSt. Petersburg, United States
  • Children's National Medical CenterWashington D.C., United States

About the trial

What the trial wants to find out

The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related donor transplants.

Read full original descriptionShow less

The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. The exact regimen depends on the subtype of SCID the patient has. Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. Once the stem cell transplant is completed, patients will be followed for 3 years. Approximately 9-18 months after the transplant, vaccinations will be administered, and a blood test measuring whether your child's body has responded to the vaccine will be collected.

The 2 groups in the trial

  • Low Dose BusulfanTreatment being tested

    Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 25-35 mg\*h/L . Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks.

    Treatment: Busulfan and Cell processing for TCRαβ+/CD19+ depletion

  • Medium Dose BusulfanTreatment being tested

    Busulfan based preparative regimen targeted at area-under-the-curve (cAUC) exposure of 55-65 mg\*h/L. Randomization between the two dose levels will be done separately in each genotype stratum (RAG1/RAG2 and IL2RG/JAK3), using permuted blocks.

    Treatment: Busulfan and Cell processing for TCRαβ+/CD19+ depletion

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Record updated
16 November 2026